Millennium Management’s Barinthus Biotherapeutics BRNS Stock Holding History

Millennium Management’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,960	Closed	-$13.2K	–	5884
2024 Q4	$13.2K	Buy	10,960 +812	+8%	+$945	﹤0.01%	5762
2024 Q3	$12.5K	Buy	+10,148	New	+$13.6K	﹤0.01%	5847
2023 Q2	–	Sell	-41,945	Closed	-$94K	–	6135
2023 Q1	$94K	Buy	41,945 +1,557	+4%	+$4.33K	﹤0.01%	5444
2022 Q4	$97K	Buy	40,388 +9,967	+33%	+$25.4K	﹤0.01%	5594
2022 Q3	$96K	Sell	30,421 -30,974	-50%	-$132K	﹤0.01%	5983
2022 Q2	$273K	Sell	61,395 -7,261	-11%	-$35K	﹤0.01%	5442
2022 Q1	$357K	Sell	68,656 -2,287	-3%	-$18.4K	﹤0.01%	5391
2021 Q4	$788K	Sell	70,943 -47,333	-40%	-$597K	﹤0.01%	4633
2021 Q3	$1.86M	Sell	118,276 -11,861	-9%	-$180K	﹤0.01%	4009
2021 Q2	$2.18M	Buy	+130,137	New	+$1.93M	﹤0.01%	3856

Other funds holding BRNS

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

JHU

Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management's BRNS Position: Q1 2025 in Review

Millennium Management sold out of Barinthus Biotherapeutics (BRNS) in Q1 2025, closing a stake of 10,960 shares — an estimated $13.2K sold.

Millennium Management first reported a position in BRNS in Q2 2021 and held it in 10 quarters. The position peaked at $2.18M in Q2 2021. 15 funds tracked by Wall St. Rank hold BRNS as of Q1 2025.

Millennium Management reported no remaining Barinthus Biotherapeutics position as of Q1 2025 after selling out during the quarter.
Millennium Management sold 10,960 Barinthus Biotherapeutics shares in Q1 2025, an estimated $13.2K.
Millennium Management first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 10 quarters.
Millennium Management's Barinthus Biotherapeutics position peaked at $2.18M in Q2 2021.
15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.